Drug Markets/ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

1 NDCs across 1 manufacturers|0 Generic,1 Brand

Total NDCs

0G / 1B

Manufacturers

competing in market

Price Spread

$150.41 – $150.41

7d Activity

1 flat

of 1 total NDCs

Monthly average NADAC price per unit, split by generic and brand

1 manufacturer producing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

1 NDCs total, 1 shown

Drug ↕	NDC	Manufacturer ↕	Price	Market Outlier	Class	7d Change ↕	Therapeutic Class
STRIBILD TABLET	61958120101	Gilead Sciences, Inc.	$150.4090 per EA	—	Brand	—	Cytochrome P450 3A Inhibitor, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor